ArticleBMC neurology2026
Associations of thyroid function, inflammatory cytokines, and ceramides with 30-day functional outcome after acute ischemic stroke.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlterations in thyroid function, inflammatory responses, and lipid metabolism have been reported in patients with acute ischemic stroke (AIS). However, the relationships between these biological changes and short-term functional outcomes, particularly in the context of thyroid dysfunction, remain incompletely understood.
methodsThis single-center retrospective cohort study included 261 patients with AIS admitted between January 2018 and December 2023. Thyroid function was assessed at admission, and patients were categorized into thyroid dysfunction (TD) and non-thyroid dysfunction (non-TD) groups. Short-term functional outcome was evaluated using the modified Rankin Scale (mRS) at 30 days. Thyroid-related indices, inflammatory cytokines, and ceramide levels obtained at admission were included in the analyses. Associations between these biomarkers and poor short-term outcome (mRS 4–6) were examined using multivariable logistic regression analyses, stratified by thyroid function status.
resultsIn the overall multivariable model, FT3 (aOR 1.19, 95% CI 1.04–1.43), Cer18:0 (aOR 1.51, 95% CI 1.18–2.21), and Cer24:1 (aOR 1.18, 95% CI 1.10–1.26) were independently associated with poor 30-day functional outcome. IL-17 A (aOR 1.37, 95% CI 1.20–1.58) and TNF-α (aOR 1.44, 95% CI 1.24–1.68) were also associated with poor outcome, whereas IL-10 showed an inverse association (aOR 0.68, 95% CI 0.59–0.78). Stratified analyses suggested differences according to thyroid dysfunction status. In the thyroid dysfunction group, FT3 was more strongly associated with poor outcome (aOR 2.33, 95% CI 1.68–4.37), whereas Cer18:0 remained positively associated in the non-thyroid dysfunction group (aOR 2.84, 95% CI 1.66–3.83).
conclusionIn this retrospective cohort of patients with acute ischemic stroke, 30-day functional outcome was associated with thyroid-related measures, inflammatory cytokines, and ceramides after multivariable adjustment. Differences according to thyroid dysfunction status may reflect coordinated changes across thyroid function, immune-inflammatory responses, and sphingolipid metabolism in the acute post-stroke setting. These findings should be interpreted cautiously and require confirmation in larger prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.